Compare NYAX & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | TMDX |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2022 | 2019 |
| Metric | NYAX | TMDX |
|---|---|---|
| Price | $67.29 | $74.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $49.50 | ★ $148.22 |
| AVG Volume (30 Days) | 10.9K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $30.66 | $24.25 |
| Revenue Next Year | $21.70 | $18.75 |
| P/E Ratio | ★ $89.78 | $369.10 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $39.17 | $60.11 |
| 52 Week High | $76.86 | $156.00 |
| Indicator | NYAX | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 51.97 |
| Support Level | $62.44 | $64.87 |
| Resistance Level | $68.79 | $80.72 |
| Average True Range (ATR) | 1.98 | 3.05 |
| MACD | -0.04 | 0.63 |
| Stochastic Oscillator | 45.81 | 69.69 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.